- Home
- IMCR vs EOSE Comparison
IMCR vs EOSE Comparison
Compare IMCR & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- EOSE
- Stock Information
- Founded
- IMCR 2008
- EOSE 2008
- Country
- IMCR United Kingdom
- EOSE United States
- Employees
- IMCR N/A
- EOSE N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- EOSE Industrial Machinery/Components
- Sector
- IMCR Health Care
- EOSE Miscellaneous
- Exchange
- IMCR Nasdaq
- EOSE Nasdaq
- Market Cap
- IMCR 1.8B
- EOSE 1.5B
- IPO Year
- IMCR 2021
- EOSE N/A
- Fundamental
- Price
- IMCR $33.38
- EOSE $5.98
- Analyst Decision
- IMCR Buy
- EOSE Strong Buy
- Analyst Count
- IMCR 10
- EOSE 3
- Target Price
- IMCR $58.13
- EOSE $6.50
- AVG Volume (30 Days)
- IMCR 315.0K
- EOSE 15.9M
- Earning Date
- IMCR 08-07-2025
- EOSE 07-30-2025
- Dividend Yield
- IMCR N/A
- EOSE N/A
- EPS Growth
- IMCR N/A
- EOSE N/A
- EPS
- IMCR N/A
- EOSE N/A
- Revenue
- IMCR $356,145,000.00
- EOSE $33,800,000.00
- Revenue This Year
- IMCR $27.43
- EOSE $945.82
- Revenue Next Year
- IMCR $8.64
- EOSE $195.86
- P/E Ratio
- IMCR N/A
- EOSE N/A
- Revenue Growth
- IMCR 26.78
- EOSE 128.49
- 52 Week Low
- IMCR $23.15
- EOSE $1.72
- 52 Week High
- IMCR $39.33
- EOSE $7.36
- Technical
- Relative Strength Index (RSI)
- IMCR 49.64
- EOSE 52.27
- Support Level
- IMCR $31.02
- EOSE $5.84
- Resistance Level
- IMCR $33.73
- EOSE $6.61
- Average True Range (ATR)
- IMCR 1.49
- EOSE 0.49
- MACD
- IMCR -0.03
- EOSE -0.05
- Stochastic Oscillator
- IMCR 44.61
- EOSE 46.34
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.